San Francisco-based diagnostic company Numen is building a single-use hardware platform designed to conduct rapid cancer screening at home. Founded in 2021 and backed by Y Combinator's Summer 2023 cohort, the team aims to lower cancer mortality by detecting early biological signatures before clinical symptoms advance.
Numen's core product is a machine-readable test strip that analyzes biomarkers from a urine sample in approximately 30 minutes without requiring laboratory equipment or clinical appointments. The initial screens focus on detecting early indications of bladder, prostate, and ovarian cancers.
Combining Molecular Biology, Systems Engineering, and Machine Learning
Numen was co-founded by CEO Luca Springer and clinical cancer researcher Thomas Carroll. The duo met at the University of Oxford, where Carroll completed a PhD in Clinical Medicine focused on bioinformatics and biomarkers. Springer holds master's degrees in computer science and global governance from Oxford, where he studied as a Rhodes Scholar with a research focus in computational game theory and network science. He previously evaluated healthcare and technology investments at Stockdale Street.
Originally launched under the name Cleancard, the company rebranded to Numen and raised approximately $5.1 million in funding. The company operates out of a 10,000-square-foot facility in San Francisco that houses molecular biology wet labs, hardware engineering facilities, and software development teams in one physical space.
Speaking in a video interview hosted by TQ Ventures, Springer explained that Numen's initial diagnostic focus targets patients presenting with microhematuria, or trace blood in the urine, a condition affecting 1 in 20 Americans, of whom 2 percent have underlying bladder cancer. Patients receive a disposable testing unit, deposit a sample, and initiate a 30-minute automated analysis. Quantitative results and optical diagnostic readings are processed via cloud infrastructure and delivered directly to healthcare providers to streamline patient referrals to urologists.
In an profile published by yespress.io, the diagnostic architecture relies on synthetic biology to capture micro-concentrations of specific disease signatures, paired with computer vision and machine learning algorithms to evaluate test outputs captured via mobile camera. The company is also assembling longitudinal datasets to construct predictive disease risk models and assist clinical trial patient selection.
Expanding the Hardware and Signal Processing Team
To advance its diagnostic measurement capabilities and scale hardware development, Numen is currently hiring across technical and design disciplines in San Francisco.
On the hardware and sensing side, Numen is recruiting a Senior Signal Processing Engineer - Biosensor Readout ($140,000 - $200,000 USD, onsite). This role owns the complete measurement pipeline from raw biosensor data to quantitative diagnostic metrics, defining readout architectures and building signal processing algorithms for the medical testing platform.
To support system assembly and embedded development, the team is hiring an Engineer I - Electromechanical Integration ($110,000 - $140,000 USD, onsite). The position involves designing custom PCBs, fabricating hardware prototypes, and writing microcontroller firmware for test setups under senior engineering mentorship.
Numen is also recruiting a Visual Designer ($90,000 - $140,000 USD, onsite) to shape the company's brand identity and digital interfaces. The designer will collaborate across engineering and product teams to implement user interfaces and scale design systems across physical and digital patient touchpoints.
Open Roles at Numen
| Role | Location | Work Mode | Salary |
|---|---|---|---|
| Engineer I - Electromechanical Integration | San Francisco, CA, US | Onsite | $110,000 - $140,000 USD |
| Senior Signal Processing Engineer - Biosensor Readout | San Francisco, CA, US | Onsite | $140,000 - $200,000 USD |
| Visual Designer | San Francisco, CA, US | Onsite | $90,000 - $140,000 USD |



